Invention Grant
- Patent Title: Chemically-locked bispecific antibodies
-
Application No.: US16388760Application Date: 2019-04-18
-
Publication No.: US11267905B2Publication Date: 2022-03-08
- Inventor: Yanwen Fu , Gunnar F. Kaufmann , James T. Patterson
- Applicant: Sorrento Therapeutics, Inc.
- Applicant Address: US CA San Diego
- Assignee: Sorrento Therapeutics, Inc.
- Current Assignee: Sorrento Therapeutics, Inc.
- Current Assignee Address: US CA San Diego
- Agency: McNeill Baur PLLC
- Main IPC: A61K39/00
- IPC: A61K39/00 ; C07K16/46 ; C07K16/28 ; C07K16/30
Abstract:
Provided are bispecific antibody compounds having the Formula I: wherein, FAB1, FAB2, and —X— are as defined herein. The provided bispecific antibody compounds can be used a modulators of target molecules, including CD3, PSMA, CD19, CXCR5, CD33, PDL1, VEGFR2, cMet, or Ax1, and are useful in the treatment of one or more conditions.
Public/Granted literature
- US20190248923A1 CHEMICALLY-LOCKED BISPECIFIC ANTIBODIES Public/Granted day:2019-08-15
Information query
